JP2005508857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508857A5 JP2005508857A5 JP2002591038A JP2002591038A JP2005508857A5 JP 2005508857 A5 JP2005508857 A5 JP 2005508857A5 JP 2002591038 A JP2002591038 A JP 2002591038A JP 2002591038 A JP2002591038 A JP 2002591038A JP 2005508857 A5 JP2005508857 A5 JP 2005508857A5
- Authority
- JP
- Japan
- Prior art keywords
- cyano
- guanidine
- pyridyl
- cancer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29292801P | 2001-05-24 | 2001-05-24 | |
| PCT/DK2002/000351 WO2002094322A2 (en) | 2001-05-24 | 2002-05-24 | Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508857A JP2005508857A (ja) | 2005-04-07 |
| JP2005508857A5 true JP2005508857A5 (https=) | 2006-01-05 |
Family
ID=23126850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002591038A Withdrawn JP2005508857A (ja) | 2001-05-24 | 2002-05-24 | 新生物疾患処置用の薬剤組み合わせ |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20030045515A1 (https=) |
| EP (1) | EP1411984B1 (https=) |
| JP (1) | JP2005508857A (https=) |
| KR (1) | KR20040007607A (https=) |
| CN (1) | CN1516600A (https=) |
| AT (1) | ATE394100T1 (https=) |
| AU (1) | AU2002316795B2 (https=) |
| BR (1) | BR0209936A (https=) |
| CA (1) | CA2449442A1 (https=) |
| CZ (1) | CZ20033189A3 (https=) |
| DE (1) | DE60226446D1 (https=) |
| HU (1) | HUP0400024A3 (https=) |
| IL (1) | IL158821A0 (https=) |
| MX (1) | MXPA03010691A (https=) |
| PL (1) | PL366462A1 (https=) |
| RU (1) | RU2291710C2 (https=) |
| WO (1) | WO2002094322A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2485351C (en) * | 2002-05-17 | 2011-12-06 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| BR0309988A (pt) * | 2002-05-17 | 2005-02-22 | Leo Pharma As | Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto |
| WO2004041285A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| AU2003295773A1 (en) * | 2002-11-21 | 2004-06-18 | Novacea, Inc. | Treatment of liver disease with active vitamin d compounds |
| US20050075341A1 (en) * | 2003-07-17 | 2005-04-07 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
| AR050253A1 (es) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
| PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
| ES2572777T3 (es) | 2004-12-22 | 2016-06-02 | Leo Pharma A/S | Compuestos novedosos de cianoguanidina |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| AR055343A1 (es) | 2005-06-30 | 2007-08-22 | Smithkline Beecham Corp | Derivados de indolcarboxamida inhibidores de quinasas ikk2 |
| CA2617692A1 (en) * | 2005-08-04 | 2007-02-08 | Bayer Healthcare Ag | Combinations containing ikk-.beta. inhibitors |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| CA2751495C (en) * | 2009-02-06 | 2013-08-20 | Tianjin Hemay Bio-Tech Co., Ltd. | Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
| EP3313819A1 (en) * | 2015-06-23 | 2018-05-02 | Case Western Reserve University | Compositions and methods for treating cancer |
| AU2017290256A1 (en) | 2016-06-29 | 2019-01-17 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9219472D0 (en) * | 1992-09-15 | 1992-10-28 | Leo Pharm Prod Ltd | Chemical compounds |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| DE69731840T2 (de) * | 1996-07-15 | 2005-08-04 | Sankyo Co., Ltd. | Pharmazeutische Zusammensetzungen enthaltend CS-866 und Insulinresistenz verbessernde Mittel und deren Verwendung zur Behandlung von Arteriosklerose und Xanthom |
| GB9711124D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711122D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711119D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711125D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711123D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
-
2002
- 2002-05-21 US US10/151,094 patent/US20030045515A1/en not_active Abandoned
- 2002-05-24 CN CNA028121880A patent/CN1516600A/zh active Pending
- 2002-05-24 PL PL02366462A patent/PL366462A1/xx not_active Application Discontinuation
- 2002-05-24 EP EP02745167A patent/EP1411984B1/en not_active Expired - Lifetime
- 2002-05-24 MX MXPA03010691A patent/MXPA03010691A/es unknown
- 2002-05-24 AU AU2002316795A patent/AU2002316795B2/en not_active Ceased
- 2002-05-24 DE DE60226446T patent/DE60226446D1/de not_active Expired - Fee Related
- 2002-05-24 RU RU2003137006/15A patent/RU2291710C2/ru not_active IP Right Cessation
- 2002-05-24 CA CA002449442A patent/CA2449442A1/en not_active Abandoned
- 2002-05-24 BR BR0209936-5A patent/BR0209936A/pt not_active IP Right Cessation
- 2002-05-24 IL IL15882102A patent/IL158821A0/xx unknown
- 2002-05-24 KR KR10-2003-7015363A patent/KR20040007607A/ko not_active Ceased
- 2002-05-24 JP JP2002591038A patent/JP2005508857A/ja not_active Withdrawn
- 2002-05-24 HU HU0400024A patent/HUP0400024A3/hu unknown
- 2002-05-24 WO PCT/DK2002/000351 patent/WO2002094322A2/en not_active Ceased
- 2002-05-24 AT AT02745167T patent/ATE394100T1/de not_active IP Right Cessation
- 2002-05-24 CZ CZ20033189A patent/CZ20033189A3/cs unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508857A5 (https=) | ||
| EP4010329B1 (en) | Deuterated compounds for use in the treatment of cancer | |
| EP1450799B2 (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers | |
| RU2003137006A (ru) | Комбинированное лекарственное средство для лечения опухолевых заболеваний | |
| AU2021202619B2 (en) | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | |
| JP2022520061A5 (https=) | ||
| JP5201995B2 (ja) | ジアザベンゾ［デ］アントラセン−３−オン化合物、及び、ｐａｒｐの阻害方法 | |
| EA032639B1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
| CA2447021A1 (en) | Pyridyl cyanoguanidine compounds | |
| WO2019094053A1 (en) | Disulfiram and copper salt dosing regimen | |
| ES3008687T3 (en) | Heterocyclic compounds for use in the treatment of cancer | |
| CN104968358A (zh) | 涉及粘液素的疾病治疗 | |
| CN1511036A (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| CA2485351A1 (en) | Cyanoguanidine prodrugs | |
| US6822001B2 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| JP2025041742A (ja) | 薬学的組合せ | |
| JP2023509191A (ja) | 癌を治療するための組み合わせ療法 | |
| TW201306833A (zh) | 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合 | |
| JP2023514426A5 (https=) | ||
| JP2010526073A (ja) | 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体 | |
| WO2020234445A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| HK40076656B (en) | Deuterated compounds for use in the treatment of cancer | |
| HK40076656A (en) | Deuterated compounds for use in the treatment of cancer | |
| HK40026061A (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor |